Evercore ISI initiated coverage on shares of Iqvia (NYSE:IQV) in a report published on Thursday, January 18th, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $112.00 price objective on the medical research company’s stock.
A number of other equities research analysts also recently weighed in on IQV. KeyCorp reissued a buy rating and set a $100.00 price target on shares of Iqvia in a research note on Sunday, September 24th. Robert W. Baird reaffirmed a hold rating and issued a $98.00 target price on shares of Iqvia in a research note on Monday, October 9th. Zacks Investment Research raised shares of Iqvia from a hold rating to a buy rating and set a $107.00 target price for the company in a research note on Wednesday, October 11th. Credit Suisse Group reaffirmed an outperform rating and issued a $110.00 target price (up previously from $98.00) on shares of Iqvia in a research note on Monday, October 16th. Finally, Stifel Nicolaus raised shares of Iqvia from a hold rating to a buy rating and upped their target price for the company from $92.00 to $128.00 in a research note on Friday, October 27th. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $109.71.
Iqvia (IQV) traded up $2.58 on Thursday, hitting $98.63. 1,257,987 shares of the company were exchanged, compared to its average volume of 1,138,950. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.22 and a current ratio of 1.22. The company has a market capitalization of $19,980.00, a P/E ratio of 340.10, a price-to-earnings-growth ratio of 1.31 and a beta of 0.61. Iqvia has a twelve month low of $75.94 and a twelve month high of $110.67.
In other news, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $99.97, for a total value of $999,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $101.79, for a total transaction of $4,690,483.20. The disclosure for this sale can be found here. Insiders sold 8,727,078 shares of company stock valued at $890,124,079 in the last quarter. Corporate insiders own 6.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. acquired a new position in shares of Iqvia in the fourth quarter valued at approximately $123,000. Valeo Financial Advisors LLC acquired a new position in Iqvia during the fourth quarter worth $170,000. IFP Advisors Inc acquired a new position in Iqvia during the fourth quarter worth $200,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Iqvia during the fourth quarter worth $209,000. Finally, Atria Investments LLC acquired a new position in Iqvia during the fourth quarter worth $218,000. Institutional investors own 95.91% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Iqvia (NYSE:IQV) Now Covered by Evercore ISI” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/12/iqvia-iqv-now-covered-by-evercore-isi.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.